z-logo
open-access-imgOpen Access
In Vitro Susceptibilities of Candida and Cryptococcus neoformans Isolates from Blood Cultures of Neutropenic Patients
Author(s) -
Daryl J. Hoban,
George G. Zhanel,
James A. Karlowsky
Publication year - 1999
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.43.6.1463
Subject(s) - fluconazole , voriconazole , fungemia , microbiology and biotechnology , candida parapsilosis , cryptococcus neoformans , candida tropicalis , itraconazole , amphotericin b , candida albicans , biology , candida krusei , ketoconazole , neutropenia , flucytosine , antifungal , chemotherapy , genetics
Fluconazole-resistantCandida albicans and intrinsically fluconazole-resistantCandida species have been reported as bloodstream isolates. However, an association between the isolation of fluconazole-resistantCandida from the bloodstream and patient risk factors for fungemia has not been established. The purpose of this study was to determine the prevalence of fluconazole resistance in bloodstream isolates ofCandida species andCryptococcus neoformans collected from patients with neutropenia, one of the most important risk factors for fungemia. MICs of voriconazole, fluconazole, itraconazole, ketoconazole, amphotericin B, and flucytosine were determined by the National Committee for Clinical Laboratory Standards M27-A method (1997). Voriconazole, on a per-weight basis, was the most active azole tested. Fluconazole resistance (MIC ≥ 64 μg/ml) was not identified in any of theC. albicans (n = 513),Candida parapsilosis (n = 78),Candida tropicalis (n = 62), orC. neoformans (n = 38) isolates tested.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom